Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation
Journal of Cystic Fibrosis, ISSN: 1569-1993, Vol: 23, Issue: 1, Page: 29-31
2024
- 5Citations
- 10Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Most Recent News
Reports Summarize Cystic Fibrosis Findings from Aristotle University of Thessaloniki (Use of Cystic Fibrosis Inhaled Medication Before and After Elexacaf Tor/tezacaf Tor/ivacaf Tor Initiation)
2024 JUN 06 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- New research on Lung Diseases and Conditions - Cystic
Article Description
Elexacator/tezacaftor/ivacaftor (ETI) has improved cystic fibrosis (CF) outcomes. A reduction in use of maintenance medication after its initiation has been reported. Seventy-one adult people with CF (PwCF) who are followed in three CF centers and completed one year of treatment with ETI were included in this study. Their use of inhaled dornase-α, colistin, tobramycin, aztreonam and levofloxacin during this period was compared with the corresponding use during one year without ETI, using the Medication Possession Ratio (MPR). MPR was significantly decreased after ETI initiation for dornase-α (67±35% vs 48±40%, p <0.001) and for all four inhaled antibiotics together (62±33% vs 41±37%, p <0.001). The findings of this multi-center, retrospective, study suggest that the initiation of ETI significantly leads to decrease in use of standard inhaled medication in PwCF. The significance of this finding in the course of the disease is yet to be investigated by larger prospective clinical trials.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1569199323001315; http://dx.doi.org/10.1016/j.jcf.2023.05.001; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85159043514&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/37169616; https://linkinghub.elsevier.com/retrieve/pii/S1569199323001315; https://dx.doi.org/10.1016/j.jcf.2023.05.001
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know